Answers are grounded in this paper and cite their sources.
INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal interstitial lung disease with limited therapies that only delay progression. Stem cell-derived extracellular vesicles (EVs) offer a promising cell-free alternative due to their immunomodulatory, anti-fibrotic, and regenerative properties. AREAS COVERED: This review systematically summarizes the molecular mechanisms by which EVs secreted from human umbilical cord mesenchymal stem cells, adipose-derived mesenchymal stem cells, bone marrow mesenchymal stem cells, and induced pluripotent stem cells inhibit pulmonary fibrosis. The article compares various administration routes and highlights nebulized inhalation as an effective delivery strategy. It also provides a rigorous evaluation of the complete clinical-grade manufacturing workflow, including stem cell culture, extracellular vesicle isolation and purification, quality control, and preservation. We have referenced relevant English medical literature from the Medline/PubMed database up to September 2026. EXPERT OPINION: Major barriers to clinical translation include donor heterogeneity, lack of standardized Good Manufacturing Practice (GMP) protocols, and storage instability. Future advances will rely on engineered EV modifications, Induced pluripotent stem cells (iPSC)-based scalable production. Within five years, nebulized MSC-EV products are expected to enter clinical practice, shifting IPF treatment from fibrosis delay toward repair, alongside existing oral anti-fibrotics.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: